May 12th 2024
Training at a major academic center offers firsthand exposure to groundbreaking 177Lu-PSMA-617 treatment for advanced prostate cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Petrylak Reviews Results From KEYNOTE-921 in mCRPC
September 28th 2023Daniel P. Petrylak, MD, discusses background and findings from the phase 3 KEYNOTE-921 study of pembrolizumab plus docetaxel vs placebo plus docetaxel in patients with metastatic castration-resistant prostate cancer who had received prior next-generation hormonal agent therapy.
Watch
In Advanced Prostate Cancer, a String of Modest Gains Are Changing Patient Care
September 27th 2023Robert Dreicer, MD, MS, MACP, FASCO, acknowledges that there have been substantial developments in therapies and strategies for treating prostate cancer, leading to heightened expectations of breakthroughs in the field.
Read More
Bryce Reviews PARP Inhibitor Combination Trials in Prostate Cancer
September 27th 2023During a Targeted Oncology™ Community Case Forum event in partnership with The Arizona Clinical Oncology Society, Alan H. Bryce, MD, reviewed data from clinical trials utilizing PARP inhibitors in patients with prostate cancer.
Read More
Analyzing Therapeutic Sequencing in Metastatic Prostate Cancer
September 19th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Joshi Alumkal, MD, discussed selection of next-line therapy for a patient with metastatic castration-resistant prostate cancer who stopped docetaxel after 4 cycles.
Read More
Safety Results with Cabazitaxel Support Wider Use in mCRPC
September 8th 2023In the second article of a 2-part series, Mehmet A. Bilen, MD, explains how further findings from the phase 3 CARD trial support the wider role cabazitaxel should have in treating patients with metastatic castration-resistant prostate cancer.
Read More
Morgans and Choudhury Break Down Prostate Cancer Treatment for Heavily Pretreated Patients
August 28th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Atish D. Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discussed with participants about selecting next-line therapy for metastatic castration-resistant prostate cancer after use of enzalutamide and docetaxel.
Read More
FDA to Quickly Review sNDA for Enzalutamide in nmCSPC With High-Risk BCR
August 23rd 2023The metastasis-free survival benefit of enzalutamide, and other efficacy and safety data are now under FDA review for the potential approval of the drug for patients with non-metastatic castration-sensitive prostate cancer.
Read More
FDA Approves Niraparib Plus Abiraterone Acetate and Prednisone for BRCA+ mCRPC
August 11th 2023Results from the phase 3 MAGNITUDE study have led to a quick FDA decision on the future of a dual action tablet for the treatment of patients with BRCA-positive metastatic castration-resistant prostate cancer.
Read More
Time to Discontinuation on Darolutamide Longer in nmCRPC
August 10th 2023Alicia K. Morgans, MD, MPH, discusses real-world evidence the shows patients with non-metastatic castration resistant prostate cancer on darolutamide have a longer time till discontinuation when compared with enzalutamide and apalutamide.
Watch
NCCN Guidelines Add Flotufolastat F 18 Injection for Prostate Cancer
July 27th 2023Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted pet imaging agent in prostate cancer. The agent has now been added to the NCCN guidelines.
Read More
Prior Pluvicto Shortage Led to Long Waiting Lists for Patients With mCRPC
July 22nd 2023Roby Thomas, MD, discusses the shortage of lutetium Lu 177 vipivotide tetraxetan, and how it had affected patients with metastatic castration-resistant prostate cancer being treated at UPMC Hillman Cancer Center.
Watch
Physicians Discuss Targeted Treatment for Prostate Cancer Subtypes
July 10th 2023In the second article of a 2-part article series, Joshua Lang, MD, and live event participants discuss the role of cabazitaxel for the treatment of patients with prostate cancer who harbor certain mutations or have other factors that make their disease unique.
Read More